Gault, Abigail
Hogarth, Linda
Williams, Kristian C
Greystoke, Alastair
Rajan, Neil
Speight, Ally
Lamb, Christopher A
Bridgewood, Alison
Brown-Schofield, Lisa-Jayne
Rayner, Fiona
Isaacs, John D
Nsengimana, Jérémie
Stewart, Christopher J
Anderson, Amy E
Plummer, Ruth
Pratt, Arthur G
Funding for this research was provided by:
Cancer Research UK
NIHR Newcastle Biomedical Research Centre
JGW Patterson Foundation (30015.088/9of19/PA/IXS, 30015.088/9of19/PA/IXS, 30015.088/9of19/PA/IXS, 30015.088/9of19/PA/IXS)
Versus Arthritis (22072, 22072, 22072, 22072)
Article History
Received: 27 November 2023
Accepted: 3 June 2024
First Online: 14 June 2024
Declarations
:
: The MEDALLION study was reviewed and approved by the East of England Research Ethics Committee on 17/01/2019 REC reference 18/EE/0400. HRA approval was gained on 18/01/2019 (IRAS ID 252992). The study is being conducted in compliance with Good Clinical Practice and the Research Governance Framework for Health and Social Care. The study is registered in the ISRCTN registry (identifier ISRCTN 43419676). The current version of the study protocol and associated appendices is available in the Online Supplementary file. All study participants provided full written, informed consent to participate in it.
: Not applicable.
: AGP has received research grant funding from, or undertaken consultancy for the following companies on behalf of Newcastle University: GSK, Pfizer, Gilead and Inflection Biosciences.RP has undertaken consultancy for Pierre Faber, Bayer, Novartis, BMS, Ellipses, Immunocore, Genmab, Astex Therapeutics, Medivir, Biosceptre, Nerviano, AmLo, Incyte, Cybrexa, Benevolent AI, Alligator Biosciences, GSK, Onxeo, SOTIO Biotech AG, AstraZeneca and Sanofi Aventis. A Greystoke has undertaken consultancy for AstraZeneca, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Janssen/ J and J, Lilly, MSD, Novartis, Pfizer, Lilly, Takeda, Roche and Sanofi Aventis. CAL reports grants from Genentech, grants and personal fees from Janssen, grants and personal fees from Takeda, grants from AbbVie, personal fees from Ferring, grants from Eli Lilly, grants from Pfizer, grants from Roche, grants from UCB Biopharma, grants from Sanofi Aventis, grants from Biogen IDEC, grants from Orion OYJ, personal fees from Dr Falk Pharma, grants from AstraZeneca, personal fees from Nordic Pharma outside the submitted work. JDI has received research grant funding from, or undertaken consultancy for the following companies on behalf of Newcastle University: Anaptys Bio, Annexon Biosciences, AstraZeneca, BMS, Cyxone AB, Eli Lilly, Galapagos NV, Gilead Sciences Ltd, GSK, Istesso Ltd, Janssen, Kenko International, Kira Biotech, Ono Pharma, Pfizer, Revelo Biotherapeutics, Roche, Sanofi. The other authors (A Gault, LH, KCW, NR, AS, AB, LB, RF, JN, CJS and AEA) declare no competing interest.